Context is dedicated to developing the next generation of T cell engaging (TCE) bispecific antibody therapies to treat solid tumors. We are building an innovative portfolio of clinical-stage T cell engaging bispecific therapeutics, including CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody, CT-95, a potential first-in-class mesothelin (MSLN) x CD3 bispecific antibody, and CT-202, a potential best-in-class Nectin-4 x CD3 bispecific antibody.
